<DOC>
	<DOC>NCT01930396</DOC>
	<brief_summary>The HEMO-TIN trial is designed to look at both the safety (bleeding risk) and effectiveness (clotting risk) of tinzaparin compared with unfractionated heparin for anticoagulation in hemodialysis patients.</brief_summary>
	<brief_title>Use of Tinzaparin for Anticoagulation in Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
	<mesh_term>Tinzaparin</mesh_term>
	<criteria>Age &gt;= 18 years End stage renal disease maintained on outpatient hemodialysis for &gt;= 3 months Frequency of hemodialysis: 3 times per week Anticoagulation with an unfractionated heparin protocol for at least 4 weeks Patient or legal guardian able to provide written consent Baseline INR &lt;= 1.3 Baseline platelet count &gt;= 80,000 x 10^9/L Therapeutic systemic anticoagulation Clinically apparent bleeding in the last 2 months High risk of bleeding Planned major surgery in the next 4 months Major surgery in the past 48 hours Pregnant or lactating Child bearing potential Allergy/intolerance to heparin or history of heparin induced thrombocytopenia Current participation in a related randomized drug trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Hemodialysis</keyword>
	<keyword>Anticoagulation</keyword>
	<keyword>Tinzaparin</keyword>
	<keyword>Unfractionated Heparin</keyword>
	<keyword>Randomized Controlled Trial</keyword>
</DOC>